{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:25:10Z","timestamp":1793391910344,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Solid organ transplant (SOT) recipients are at increased risk for severe respiratory syncytial virus (RSV) disease due to chronic immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this ongoing, open-label, phase 3 trial, adults \u226518 years with a history of liver, kidney, or lung transplant received 2 doses of mRNA-1345 RSV vaccine (50 \u00b5g) 56 days apart. Primary endpoints were tolerability, safety, and RSV-A\/RSV-B neutralizing antibody (nAb) responses on Day 85; secondary endpoints included immunogenicity on Days 29 and 181. Cell-mediated immunity was an exploratory endpoint assessed in a subset of participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>146\/150 participants (median: age, 57 years; time since transplant, 4.7 years) received both doses. Reactogenicity was mild to moderate and transient. No vaccine-related discontinuations, deaths, adverse events of special interest (AESIs), or events of transplant rejection were reported within 28 days after any dose. One dose was immunogenic across all SOT types, with 4.9- and 3.4-fold increases in RSV-A\/RSV-B nAb GMTs by Day 29, respectively. A second dose resulted in modest additional increases over baseline (RSV-A, 7.1-fold; RSV-B, 5.2-fold). Added benefit of the second dose was more apparent in participants with kidney and lung transplant, &amp;lt;2 years post-transplant, and on mycophenolate. Responses remained above baseline through Day 181. Polyfunctional CD4\u207a T-cell responses were robust and sustained; CD8\u207a responses were also observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>mRNA-1345 was well tolerated and immunogenic in SOT recipients. A single dose induced nAb responses across subgroups, with potential additional benefit from a second dose in specific groups. Durable antibody and cellular responses support mRNA-1345 as a preventive strategy for RSV in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT06067230.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag108","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:46:19Z","timestamp":1771418779000},"page":"e1112-e1121","source":"Crossref","is-referenced-by-count":7,"title":["Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-8670","authenticated-orcid":false,"given":"Erick F","family":"Mayer","sequence":"first","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-9701","authenticated-orcid":false,"given":"Ann R","family":"Falsey","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine , Rochester, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-5030","authenticated-orcid":false,"given":"Cameron R","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Herc","sequence":"additional","affiliation":[{"name":"Henry Ford Hospital , Detroit, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-2441","authenticated-orcid":false,"given":"Fiona","family":"Burns","sequence":"additional","affiliation":[{"name":"University College London & Royal Free London NHS Foundation Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-1098","authenticated-orcid":false,"given":"Dima","family":"Kabbani","sequence":"additional","affiliation":[{"name":"University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Mannan","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahua","family":"She","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9943-6080","authenticated-orcid":false,"given":"Shannon","family":"McGrath","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-3982","authenticated-orcid":false,"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026052019270959500_ciag108-B1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2026052019270959500_ciag108-B2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/CMR.13.3.371","article-title":"Respiratory syncytial virus infection in adults","volume":"13","author":"Falsey","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"2026052019270959500_ciag108-B3","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/cid\/ciaa730","article-title":"Respiratory syncytial virus\u2013associated hospitalizations among adults with chronic medical conditions","volume":"73","author":"Prasad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026052019270959500_ciag108-B4","first-page":"20499361221091413","article-title":"Review of respiratory syncytial virus infection among older adults and transplant recipients","volume":"9","author":"Villanueva","year":"2022","journal-title":"Ther Adv Infect Dis"},{"key":"2026052019270959500_ciag108-B5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijid.2017.07.011","article-title":"Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles","volume":"62","author":"Abbas","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2026052019270959500_ciag108-B6","volume-title":"Respiratory viral infections in transplant recipients","author":"Liu","year":"2018"},{"key":"2026052019270959500_ciag108-B7","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.3390\/jcm14134803","article-title":"Impact of RSV infection in transplant and immunocompromised population: incidence and co-infections: retrospective analysis of a single centre","volume":"14","author":"Solidoro","year":"2025","journal-title":"J Clin Med"},{"key":"2026052019270959500_ciag108-B8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0031-1283286","article-title":"Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients","volume":"32","author":"Weigt","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"2026052019270959500_ciag108-B9","doi-asserted-by":"crossref","first-page":"e258322","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026052019270959500_ciag108-B10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/vaccines13030328","article-title":"Immunogenicity and safety of the bivalent respiratory syncytial virus prefusion F subunit vaccine in immunocompromised or renally impaired adults","volume":"13","author":"Almeida","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026052019270959500_ciag108-B11","author":"Moderna"},{"key":"2026052019270959500_ciag108-B12"},{"key":"2026052019270959500_ciag108-B13","author":"Moderna"},{"key":"2026052019270959500_ciag108-B14","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1093\/infdis\/jiae316","article-title":"Humoral immunogenicity of mRNA-1345 RSV vaccine in older adults","volume":"230","author":"Goswami","year":"2024","journal-title":"J Infect Dis"},{"key":"2026052019270959500_ciag108-B15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV preF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052019270959500_ciag108-B16","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1093\/cid\/ciaf292","article-title":"Safety, tolerability, and immunogenicity of mRNA-1345 in adults at increased risk for RSV disease aged 18 to 59 years","volume":"81","author":"Mayer","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026052019270959500_ciag108-B17","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1093\/infdis\/jiae140","article-title":"Safety and immunogenicity of the mRNA-1273 coronavirus disease 2019 vaccine in solid organ transplant recipients","volume":"230","author":"Figueroa","year":"2024","journal-title":"J Infect Dis"},{"key":"2026052019270959500_ciag108-B18","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/s41467-025-61153-x","article-title":"Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial","volume":"16","author":"Ma","year":"2025","journal-title":"Nat Commun"},{"key":"2026052019270959500_ciag108-B19","volume-title":"IDWeek","author":"Mayer","year":"2025"},{"key":"2026052019270959500_ciag108-B20","author":"Gerber"},{"key":"2026052019270959500_ciag108-B21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cmi.2020.07.050","article-title":"Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study","volume":"27","author":"Testaert","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026052019270959500_ciag108-B22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1164\/rccm.201002-0211OC","article-title":"Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients","volume":"182","author":"Finlen Copeland","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026052019270959500_ciag108-B23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"2026052019270959500_ciag108-B24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O'Brien","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026052019270959500_ciag108-B25","doi-asserted-by":"crossref","first-page":"e4421-e7","DOI":"10.1093\/cid\/ciaa648","article-title":"Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life","volume":"73","author":"Buchwald","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag108\/66990492\/ciag108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e1112\/66990492\/ciag108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e1112\/66990492\/ciag108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:27:13Z","timestamp":1779319633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/5\/e1112\/8490424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag108","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,2,18]]}}}